Primary Outcome Measures
Time to symptomatic progression (TTSP) from study entry [Time Frame: Up to 6 years] [Designated as safety issue: ]
Secondary Outcome Measures
Overall survival (OS) from time of study entry [Time Frame: Up to 6 years] [Designated as safety issue: ]
Progression free survival (PFS) from time of study entry [Time Frame: Up to 6 years] [Designated as safety issue: ]
OS from time of being diagnosed as radioactive iodine (RAI) refractory [Time Frame: Up to 6 years] [Designated as safety issue: ]
Post-progression survival (PPS) from time of symptomatic progression [Time Frame: Up to 6 years] [Designated as safety issue: ]
OS from initiation of the first Multikinase Inhibitor (MKI) [Time Frame: Up to 6 years] [Designated as safety issue: ]
PFS from initiation of first MKI [Time Frame: Up to 6 years] [Designated as safety issue: ]
OS from initiation of any systemic treatment regimen [Time Frame: Up to 6 years] [Designated as safety issue: ]
PFS from initiation of any systemic treatment regimen [Time Frame: Up to 6 years] [Designated as safety issue: ]
Duration of each systemic treatment regimen [Time Frame: Up to 6 years] [Designated as safety issue: ]
Response assessment to each systemic treatment regimen according to the categories "Complete Response", "Partial Response", "Stable Disease", "Clinical Progression", "Radiological Progression", and "Not evaluable at this visit" [Time Frame: Up to 6 years] [Designated as safety issue: ]
OS from initiation of sorafenib [Time Frame: Up to 6 years] [Designated as safety issue: ]
PFS from initiation of sorafenib [Time Frame: Up to 6 years] [Designated as safety issue: ]
Daily dose of sorafenib per patient throughout the treatment period [Time Frame: Up to 6 years] [Designated as safety issue: ]
Number of adverse events during treatment with sorafenib [Time Frame: Up to 6 years] [Designated as safety issue: ]